August 14, 2025: The Patient, Consumer, and Public Health Coalition's written comment discusses concerns about PDUFA reauthorization and urges the FDA to prioritize safety instead of just speed and to increase transparency and patient involvement.| Patient, Consumer, and Public Health Coalition
August 4th, 2025: Tess Robertson-Neel testified on behalf of the Patient, Consumer, and Public Health Coalition at the FDA MDUFA Reauthorization Public Meeting. The coalition supports the reauthorization of MDUFA but made suggestions for making MDUFA more patient and public health centered.| Patient, Consumer, and Public Health Coalition
The Promising Pathways Act has no safeguards for protecting patients from drugs that have no benefits. It has the potential to greatly tarnish patients’ trust in the FDA and in new treatments approved by the FDA.| Patient, Consumer, and Public Health Coalition